Closely allied with (both) Mercks and Celgene, Sutro CEO Bill Newell is laying out all his cards in a new IPO
Sutro CEO Bill Newell didn’t hide his interest in an IPO last year, after he retooled a pact with Celgene that eliminated their buyout option …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
